While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM ...

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and ...

Davey Daniel, MD, chief medical officer at OneOncology, stresses the need for real-world evidence in genomic testing to improve patient outcomes and cost-effectiveness.

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced ...

Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, ...

Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...

The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and ...

It’s hard for practicing oncologists to stay on top of the latest clinical data, but good partnerships and clinical decision ...

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and ...